WHO ICTRP trial
Effect of cladribine treatment on microglial activation in the CNS
CTIS2024-519921-39-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-519921-39-00 |
|---|---|
| Public title | Effect of cladribine treatment on microglial activation in the CNS |
| Scientific title | Effect of cladribine treatment on microglial activation in the CNS |
| Primary sponsor | Varsinais-Suomen hyvinvointialue |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): Yes |
| Countries | Finland |
| Conditions | Multiple Sclerosis MedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852;Therapeutic area: Diseases [C] - Immune System Diseases [C20];Therapeutic area: Diseases [C] - Nervous System Diseases… |
| Interventions | Product Name: MAVENCLAD 10 mg tablets, Product Code:PRD5373276, Pharmaceutical Form: TABLET, Other descriptive name: , Strength: |
| Registration date | Feb 12, 2024 |
| Target size | 15 |
| Secondary IDs | NCT04239820;2019-001960-31 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: